Detalhe da pesquisa
1.
Health-Related Quality of Life Outcomes With Two Different Starting Doses of Lenvatinib in Combination With Everolimus for Previously Treated Renal Cell Carcinoma.
Oncologist
; 28(1): 59-71, 2023 01 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-35881028
2.
The Cost-Effectiveness of Lenvatinib in the Treatment of Advanced or Unresectable Hepatocellular Carcinoma from a Canadian Perspective.
Can J Gastroenterol Hepatol
; 2021: 8811018, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-33681090
3.
Cost-Effectiveness of Lenvatinib in the Treatment of Patients With Unresectable Hepatocellular Carcinomas in Japan: An Analysis Using Data From Japanese Patients in the REFLECT Trial.
Value Health Reg Issues
; 24: 82-89, 2021 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-33524900
4.
Metastatic Renal Cell Cancer: An Analysis of Reimbursement Decisions.
Adv Ther
; 36(6): 1266-1278, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30953332
5.
Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan.
J Gastroenterol
; 54(6): 558-570, 2019 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-30788569
6.
Learning a Continuous-Time Streaming Video QoE Model.
IEEE Trans Image Process
; 27(5): 2257-2271, 2018 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-29432105
7.
Loss of ACE2 exacerbates murine renal ischemia-reperfusion injury.
PLoS One
; 8(8): e71433, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-23951161